Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

被引：0

作者：

Tjalf Ziemssen

Michael Lang

Stephan Schmidt

Holger Albrecht

Luisa Klotz

Judith Haas

Christoph Lassek

Stefan Lang

Veronika E. Winkelmann

Benjamin Ettle

Ulf Schulze-Topphoff

机构：

[1] University of Technology,Center of Clinical Neuroscience, Neurological University Clinic Carl Gustav Carus

[2] NeuroPoint Patient Academy and Neurological Practice,Department of Neurology

[3] Health Center St. Johannes,Center for Multiple Sclerosis

[4] Neurological Practice,undefined

[5] University Hospital Münster,undefined

[6] Jewish Hospital Berlin,undefined

[7] Neurological Practice,undefined

[8] Kassel and Vellmar,undefined

[9] Scientific and Medical Writing,undefined

[10] Novartis Pharma GmbH,undefined

来源：

Journal of Neurology | 2022年 / 269卷

关键词：

Relapsing–remitting multiple sclerosis; Fingolimod; Real-world; Safety; Effectiveness;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：3276 / 3285

页数：9

共 50 条

[41] Long-term effectiveness and safety of lacosamide as adjunctive therapy in children and adolescents with refractory epilepsy: a real-world study
Ting Zhao
Lu-hai Yu
Hui-lan Zhang
Jing Yu
Jie Feng
Ting-ting Wang
Yan Sun
Hong-jian Li
BMC Pediatrics, 23
[42] PANGAEA: Effectiveness and safety of fingolimod over 5 years in daily clinical practice
Ziemssen, Tjalf
Lang, Michael
Tackenberg, Bjorn
Schmidt, Stephan
Albrecht, Holger
Haas, Judith
Klotz, Luisa
Lassek, Chrstoph
Cornelissen, Christian
Schulze-Topphoff, Ulf
NEUROLOGY, 2019, 92 (15)
[43] Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
Butzkueven, Helmut
Kappos, Ludwig
Wiendl, Heinz
Trojano, Maria
Spelman, Tim
Chang, Ih
Kasliwal, Rachna
Jaitly, Seema
Campbell, Nolan
Ho, Pei-Ran
Licata, Stephanie
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (06): : 660 - 668
[44] Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab
Ziemssen, Tjalf
Lang, Michael
Tackenberg, Bjoern
Schmidt, Stephan
Albrecht, Holger
Klotz, Luisa
Haas, Judith
Lassek, Christoph
Cornelissen, Christian
Ettle, Benjamin
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
[45] Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting
Shalit, P
Farrell, P
Lindgren, P
AIDS, 2001, 15 (06) : 804 - 805
[46] Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients
Ziemssen, Tjalf
Albrecht, Holger
Haas, Judith
Klotz, Luisa
Lang, Michael
Lassek, Christoph
Schmidt, Stephan
Ettle, Benjamin
Schulze-Topphoff, Ulf
FRONTIERS IN NEUROLOGY, 2021, 12
[47] LONG-TERM EFFICACY AND SAFETY OF RISANKIZUMAB: A RETROSPECTIVE, MULTICENTER, REAL-WORLD STUDY
Kim, Han-Na
Woo, Bin
Kim, Young Chan
Kim, Dai-Hyun
Son, Sang Wook
Baek, Yoo Sang
ACTA DERMATO-VENEREOLOGICA, 2024, 104
[48] Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry
Yau, Yuk Kam
Lau, Louis Ho Shing
Lui, Rashid Nok Shun
Wong, Sunny Hei
Guo, Cosmos Liutao
Mak, Joyce Wing Yan
Ching, Jessica Yuet Ling
Ip, Margaret
Kamm, Michael A.
Rubin, David T.
Chan, Paul Kay Sheung
Chan, Francis Ka Leung
Ng, Siew Chien
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (03) : 611 - 620
[49] Short term real-world Fingolimod efficacy and safety in Emirati patients with multiple sclerosis
Ceccarelli, Antonia
Mifsud, Victoria
Abusamra, Eslam
Hussain, Syed Irteza
JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 71 : 39 - 42
[50] Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany
Ziemssen, Tjalf
Lang, Michael
Tackenberg, Bjoern
Schmidt, Stephan
Albrecht, Holger
Klotz, Luisa
Haas, Judith
Lassek, Christoph
Couto, C. Anne-Marie
Findlay, John A.
Cornelissen, Christian
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (03):

← 1 2 3 4 5 →